Radnet (RDNT)
NASDAQ:RDNT
Want to see RDNT full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.19Last Year’s EPS
0.31Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and financial results: record Q1 revenue and adjusted EBITDA, meaningful advanced-imaging growth, rapid ARR expansion and a robust sales pipeline in Digital Health, strategic acquisitions and healthy liquidity. Headwinds include weather-related Q1 impacts, short-term margin dilution in Digital Health from acquisitions and investments, seasonal first-quarter expense headwinds, and ongoing payer/reimbursement work for AI monetization. Overall, management raised imaging guidance, reaffirmed Digital Health guidance, and emphasized tangible productivity gains from AI deployments, indicating confidence in durable growth despite near-term investment-driven margin pressure.Company Guidance
Record Q1 Revenue and Adjusted EBITDA
Company delivered record first quarter results: revenue up 22.1% year-over-year and adjusted EBITDA up 36.3% year-over-year. Adjusted EBITDA margin improved by 115 basis points versus prior-year quarter (and improved 52 basis points after normalizing for weather and wildfire impacts).
Strong Advanced-Imaging Mix and Same-Center Volume Growth
Advanced imaging comprised 29.3% of procedural volume versus 26.9% a year earlier (+235 bps). Same-center advanced imaging procedure volumes grew 8.2% year-over-year; MRI same-center growth ~10.1%, CT mid-single digits, PET/CT up 35.2% aggregate and 14.7% on a same-center basis—driving outsized revenue contribution (advanced imaging represents >60% of revenue while ~29% of volume).
Digital Health Momentum and ARR Growth
DeepHealth ended Q1 with $97 million in annual recurring revenue (ARR), a 95% year-over-year increase. Management reiterated a year-end ARR target of >$140 million. Q1 commercial wins included $16 million in total contract value across 40 customers, $7 million of signed ARR not yet live, and a pipeline exceeding $150 million TCV. External revenue from Digital Health reached 64% (up from 51%).
Guidance Raised for Imaging Center Business
Following strong March performance that continued into April and May, company raised 2026 imaging center guidance: imaging revenue increased by $30 million at both low and high ends, adjusted EBITDA increased by $5 million at both low and high ends, and free cash flow guidance increased by $7 million at both low and high ends.
Strategic Acquisitions and JV Expansion
Completed three notable acquisitions: Radiology Regional (13 centers, Southwest Florida), Northwest Radiology (6 centers, Indiana), and Gleamer (France). Began a new 51% JV with Trinity Health St. Alphonsus (Boise, Idaho) for an entity generating ~ $30 million annual revenue; 155 of 440 centers (35.2%) now operate within health system partnerships. Recent imaging acquisitions contribute to growth and are being integrated with DeepHealth solutions.
Operational Productivity and AI Deployments
TechLive remote scanning reduced exam room closure hours and improved MRI utilization. Thyroid ultrasound AI reduced slot times from 30 to 20 minutes (~33% efficiency gain) across nearly 300 sites. X-ray AI live in California covering >20% of regional volume. DeepHealth and third-party AI now cover ~70% of studies across mammography, MR, CT, ultrasound and X-ray.
Strong Liquidity and Improved Receivables
Quarter-end cash balance of $455.3 million, full availability of a $282 million revolving credit facility. Net debt (debt at par less cash) $631 million and net debt to adjusted EBITDA ratio approximately 2.0. Days sales outstanding (DSO) improved to a record low of 29.5 days, driven by better patient collections and revenue-cycle improvements.
Regulatory and Product Acceleration
DeepHealth reported 26 FDA clearances and 22 CE marks to date, with expectations for ~12 additional FDA clearances and ~15 additional CE marks this year; regulatory approval velocity up >70% year-over-year.
RDNT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RDNT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 02, 2026 | $69.81 | $75.22 | +7.75% |
Feb 27, 2025 | $57.60 | $55.47 | -3.70% |
Aug 07, 2024 | $56.89 | $61.67 | +8.40% |
May 08, 2024 | $50.63 | $53.57 | +5.81% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Radnet (RDNT) report earnings?
Radnet (RDNT) is schdueled to report earning on Aug 11, 2026, TBA (Confirmed).
What is Radnet (RDNT) earnings time?
Radnet (RDNT) earnings time is at Aug 11, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RDNT EPS forecast?
RDNT EPS forecast for the fiscal quarter 2026 (Q2) is 0.19.